IBDEI0DJ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6213,0)
 ;;=E10.621^^30^388^7
 ;;^UTILITY(U,$J,358.3,6213,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6213,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,6213,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,6213,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,6214,0)
 ;;=E10.622^^30^388^11
 ;;^UTILITY(U,$J,358.3,6214,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6214,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,6214,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,6214,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,6215,0)
 ;;=E10.65^^30^388^10
 ;;^UTILITY(U,$J,358.3,6215,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6215,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycermia
 ;;^UTILITY(U,$J,358.3,6215,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,6215,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,6216,0)
 ;;=E10.39^^30^388^9
 ;;^UTILITY(U,$J,358.3,6216,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6216,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Ophthalmic Complications NEC
 ;;^UTILITY(U,$J,358.3,6216,1,4,0)
 ;;=4^E10.39
 ;;^UTILITY(U,$J,358.3,6216,2)
 ;;=^5002603
 ;;^UTILITY(U,$J,358.3,6217,0)
 ;;=E66.3^^30^388^45
 ;;^UTILITY(U,$J,358.3,6217,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6217,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,6217,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,6217,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,6218,0)
 ;;=E89.1^^30^388^49
 ;;^UTILITY(U,$J,358.3,6218,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6218,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,6218,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,6218,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,6219,0)
 ;;=H40.9^^30^389^9
 ;;^UTILITY(U,$J,358.3,6219,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6219,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,6219,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,6219,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,6220,0)
 ;;=H26.9^^30^389^5
 ;;^UTILITY(U,$J,358.3,6220,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6220,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,6220,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,6220,2)
 ;;=^5005363
 ;;^UTILITY(U,$J,358.3,6221,0)
 ;;=H10.9^^30^389^8
 ;;^UTILITY(U,$J,358.3,6221,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6221,1,3,0)
 ;;=3^Conjunctivitis,Unspec
 ;;^UTILITY(U,$J,358.3,6221,1,4,0)
 ;;=4^H10.9
 ;;^UTILITY(U,$J,358.3,6221,2)
 ;;=^5004716
 ;;^UTILITY(U,$J,358.3,6222,0)
 ;;=H11.32^^30^389^6
 ;;^UTILITY(U,$J,358.3,6222,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6222,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Left Eye
 ;;^UTILITY(U,$J,358.3,6222,1,4,0)
 ;;=4^H11.32
 ;;^UTILITY(U,$J,358.3,6222,2)
 ;;=^5004783
 ;;^UTILITY(U,$J,358.3,6223,0)
 ;;=H11.31^^30^389^7
 ;;^UTILITY(U,$J,358.3,6223,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6223,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Right Eye
 ;;^UTILITY(U,$J,358.3,6223,1,4,0)
 ;;=4^H11.31
 ;;^UTILITY(U,$J,358.3,6223,2)
 ;;=^5004782
 ;;^UTILITY(U,$J,358.3,6224,0)
 ;;=H01.002^^30^389^3
 ;;^UTILITY(U,$J,358.3,6224,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6224,1,3,0)
 ;;=3^Blepharitis Unspec,Right Lower Eyelid
 ;;^UTILITY(U,$J,358.3,6224,1,4,0)
 ;;=4^H01.002
 ;;^UTILITY(U,$J,358.3,6224,2)
 ;;=^5004239
 ;;^UTILITY(U,$J,358.3,6225,0)
 ;;=H01.004^^30^389^2
 ;;^UTILITY(U,$J,358.3,6225,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6225,1,3,0)
 ;;=3^Blepharitis Unspec,Left Upper Eyelid
 ;;^UTILITY(U,$J,358.3,6225,1,4,0)
 ;;=4^H01.004
 ;;^UTILITY(U,$J,358.3,6225,2)
 ;;=^5004241
 ;;^UTILITY(U,$J,358.3,6226,0)
 ;;=H01.005^^30^389^1
 ;;^UTILITY(U,$J,358.3,6226,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6226,1,3,0)
 ;;=3^Blepharitis Unspec,Left Lower Eyelid
